Key Takeaways
- Volume-led 22.7% YoY revenue jump: All growth came from a 33% volume surge, with zero price contribution; currency depreciation was offset by equivalent raw material imports.
- Margins improved despite supply chaos: EBITDA margin hit 18.1% in Q4 as higher inventory proved a "blessing in disguise" during a 3-month raw material supply crisis, letting the company navigate import delays of up to 12 weeks.
- A 15-year anchor contract landed: The long-term agreement, with an advance of INR51.4 cr received, locks in revenue starting FY28 and de-risks the capacity build-out.
- FY27 volume growth guided at 35–45%: Driven by utilization rising above 75%, new customer additions in the Americas and Asia, and price increases that only began kicking in from April.
- What to watch next quarter: Whether the 10–15% price increase taken in late March actually sticks through Q1, the pace of working capital reduction toward the 170-day target, and any sign that the raw material supply chain is normalizing from the current 8–12 week delays.
Volume Engine & the Price Question
- Volume growth was broad but industrial-led: Maximum volume growth came from the industrial segment, with a slight dip on the consumer side; rubber, lube additives and all segments contributed well.
- Price growth was absent until the final days: The 10–15% price increase happened only in the last 10 days of March; price changes happen quarterly or every 6 months with major customers, so price growth is "really kicking from April onwards."
- Price pass-through is never complete: When raw material prices increase, margins come under pressure because one cannot pass on 100%; some absorption is necessary due to relationship or contract nature.
- Americas got a tariff tailwind: Tariffs helped expand sales in Q4; the Americas market is doing very well and steady responses are expected for FY27 onwards.
- Asia is the new frontier: The company is venturing into the Asian market, where it was not highly penetrated previously.
- Domestic demand held firm: Driven mainly by the industrial segment; new customers were added and existing customers increased their share, possibly due to supply issues from other suppliers; the higher domestic share in Q4 did not hurt margins.
Parag Jhaveri: "Let me be honest. Neither I have a crystal ball nor I have a source from a White House, which can give you that information, what's going to happen tomorrow."
Supply Chain: The Crisis That Inventory Saved
- Import timelines stretched 2–3x: Imports that typically took 3–4 weeks were delayed to 8–12 weeks; exports to the USA that took 25 days now take 60–70 days.
- Petrochemical derivatives saw "fancy" pricing: Raw material unavailability or extreme price spikes hit the supply chain, but Yasho navigated it because it was holding high inventory.
- High stock was accidental insurance: Management called the elevated inventory a "blessing in disguise" that let the company manage the last 3 months of supply challenges well.
- Sulfur availability is tight but manageable: There is a challenge, not a problem; availability exists, but Yasho does not hold much sulfur inventory as it is one of the cheapest raw materials.
- Price volatility is contained to a few inputs: Volatility was seen in a couple of solvents and sulfur-based chemistry; besides that, prices are quite stable.
- Working capital reduction is now a stated goal: The target is to bring working capital down to 175–170 days in the next 6 to 12 months, from the elevated levels that the inventory build-up created.
Parag Jhaveri: "let me be honest, higher stock has helped us a lot in this crisis that was blessing in disguise to us. okay? So we could navigate very well with the last 3 months supply challenges of raw materials since we had enough stock, we could manage it well."
The FY28 Roadmap: INR1,500 cr with a Contract Anchor
- The 15-year agreement is the cornerstone: The long-term agreement secured an advance of INR51.4 cr; execution is progressing as planned and revenue is expected to start in FY28.
- The MNC project plant commercializes in FY28: All advances received will be set up against future deliveries.
- Utilization is the margin lever: The target is over 75% utilization in FY27, supporting EBITDA margin expansion; the FY28 revenue target of INR1,500 cr assumes asset utilization at 85–90%.
- New molecules must clear a INR50 cr bar: Management is looking at each molecule to add nothing less than INR50 cr to the top line; molecules giving INR5–10 cr revenue are not interesting.
- Beyond rubber and lube, but not into semicon: The company is working on performance chemicals beyond its traditional rubber and lube additives business, but clarified it is not in semiconductors or data centers; it remains a purely chemical B2B producer.
- Europe team is maturing: The on-ground team in Europe is now almost 1 year old, getting more mature, and expected to deliver better results.
- Pakhajan can double its production buildings: Two production buildings are built; an additional four can be constructed one by one as ramp-up or additional demand comes in.
Parag Jhaveri: "we are looking at each molecule nothing less than INR50 crores, at least to add to our top line. Otherwise, we are not interested to look at some molecule which just give us a revenue of INR5 crores."
Margin Architecture
- Q4 margin improved to 18.1%: Driven by improved execution, cost management, sourcing efficiencies and plant productivity; full-year margin was 17.4%, supported by product mix, operating leverage and cost optimization.
- FY27 margin target is around 20%: Management expects at least 2–3% higher EBITDA compared to the current year, driven by operational efficiencies from higher utilization.
- Gross margin guidance is 40–42%: Higher utilization will help leverage fixed expenses and improve margins.
- Product mix shifted away from low-margin products: Margins held despite crude volatility because the sourcing team maneuvered the supply chain and the product mix moved toward reasonable-margin products.
- FY28 margins will be maintained: Management committed to holding margins at the improved levels even as revenue scales to INR1,500 cr.
Capital Allocation & Balance Sheet
- FY26 capex was INR75 cr: About INR40 cr of that went to Pakhajan as additional capex.
- FY27 capex is set at INR125 cr: Fully funded through internal accruals, purely at Pakhajan, for new product launches or expansions; this is separate from the MNC strategic contract.
- Debt comfort zone is 2.5x Debt-to-EBITDA: The absolute debt number could rise but the ratio will remain at that level.
- Prepayment de-risked FY27 liabilities: INR23.30 cr of FY27 liabilities were prepaid, leaving only INR15.6 cr due.
- The R&D facility is now operational: Completed in October 2025, it is now fully operational, accelerating innovation and strengthening the portfolio.
The EV Question & Structural Demand
- EVs are not a threat for 15–20 years: Management sees no threat to the lubricant business in the near to medium to long term, citing a 10–15 year horizon.
- New demand pools are emerging for lubricants: Lubricant demand is growing from data centers, solar, turbine and wind power applications.
- Yasho does not compete with its customers: The company makes only pure chemicals, not formulations; all its customers are formulators, and the policy is never to compete with them.
Parag Jhaveri: "I don't see a big threat in near to the medium to long term, 10, 15 years horizon, we don't see a threat on our business of lubricant."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue target | INR1,500 cr, driven by 85–90% utilization, FY28 plant commercialization, and new molecules | FY28 |
| EBITDA margin | Around 20%, at least 2–3% higher than FY26 | FY27 |
| Gross margin | 40% to 42% | Ongoing |
| Volume growth | 35% to 45% | FY27 |
| Utilization | Over 75% | FY27 |
| Capex | INR125 cr, fully funded by internal accruals, at Pakhajan | FY27 |
| Working capital days | Reduce to 175–170 days | Next 6–12 months |
| Long-term contract revenue | Begin realizing | FY28 |
| MNC project plant | Commercial operation | FY28 |
| Debt-to-EBITDA | Maintain at 2.5x comfort level | Ongoing |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹246.72 cr, up 33% YoY |
| EBITDA | ₹44.71 cr, margin at 18.1%, reflecting 23.7% growth |
| Volume growth | 33% YoY for FY26 |
| Industrial Chemicals revenue share | 87% of revenue for both Q4 and full year |
| Exports revenue share | 62% of revenue |
| Cash from operations | ₹152.75 cr in FY26 |
| Debt-to-EBITDA | 3.75x, improved from 4.70x in FY25 |
| FY27 liabilities prepaid | ₹23.30 cr prepaid, leaving only ₹15.6 cr due |
| FY26 capex | ₹75 cr |
| Advance received on long-term contract | ₹51.4 cr |
| Plant utilization | Above 60% in FY26, between 60% and 62% in March |
| FY27 utilization target | Over 75% |
| FY27 planned capex | ₹125 cr, fully funded through internal accruals |
| FY27 volume growth guidance | 35% to 45% |
| FY28 revenue target | ₹1,500 cr |